Zobrazeno 1 - 10
of 38
pro vyhledávání: ''
Autor:
Kathy B. Baumgartner, Stephanie D. Boone, Yunfeng Cao, Avonne E. Connor, Kala Visvanathan, Richard N. Baumgartner
Publikováno v:
npj Breast Cancer, Vol 6, Iss 1, Pp 1-8 (2020)
NPJ Breast Cancer
NPJ Breast Cancer
Physical activity is recommended for most cancer patients as a nonpharmacological therapy to improve prognosis. Few studies have investigated the association between physical activity and breast cancer prognosis by ethnicity, biological, and modifiab
Autor:
Lixi Li, Jingtong Zhai, Xiuwen Guan, Haili Qian, Hui Li, Quchang Ouyang, Jin Li, Binliang Liu, Fei Ma, Binghe Xu, Chunxiao Li, Yanfang Guan, Guohua Rong, Ling Yang, Zongbi Yi, Wenna Wang, Xin Yi, Chang Lianpeng, Xuefeng Xia, Lifeng Li
Publikováno v:
npj Breast Cancer, Vol 6, Iss 1, Pp 1-8 (2020)
NPJ Breast Cancer
NPJ Breast Cancer
Human epidermal growth factor receptor 2 (HER2) protein overexpression or gene amplification is an important predictive biomarker for identifying patients with breast cancer, who may benefit from HER2-targeted therapy. However, little is known about
Autor:
Regina Barragan-Carrillo, Ana S. Ferrigno, Cynthia De la Garza-Ramos, Hatem A. Azim, Cynthia Villarreal-Garza, Matteo Lambertini
Publikováno v:
npj Breast Cancer, Vol 6, Iss 1, Pp 1-9 (2020)
NPJ Breast Cancer
NPJ Breast Cancer
Risk stratification by genomic signatures has been shown to improve prognostication and guide treatment decisions among patients with hormone-sensitive breast cancer. However, their role in young women has not been fully elucidated. In this review, a
Autor:
Xiang Zhang, Guo Chao Zhong, Guosheng Ren, Zhu Yue Li, Qing Li, Yang Shi, Tingxiu Xiang, James R. Hébert, Kang Wang, Theodoros Foukakis, Hong Yuan Li, Jia Zheng Sun, Nitin Shivappa, Jiali Zheng, Da Xue Li, Qian Xue Wu, Yong Fu Xiong
Publikováno v:
npj Breast Cancer, Vol 6, Iss 1, Pp 1-11 (2020)
NPJ Breast Cancer
NPJ Breast Cancer
Inflammation-modulating nutrients and inflammatory markers are established cancer risk factors, however, evidence regarding the association between post-diagnosis diet-associated inflammation and breast cancer survival is relatively sparse. We aimed
Autor:
Athina Kostara, Hakima Harrach, Mattea Reinisch, Mark H Dyson, Rita K. Schmutzler, Ouafaa Chiari, Sherko Kuemmel, Katja Ziegler-Löhr
Publikováno v:
npj Breast Cancer, Vol 6, Iss 1, Pp 1-4 (2020)
NPJ Breast Cancer
NPJ Breast Cancer
There is a strong biologic rationale that poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors may benefit a broader range of metastatic breast cancer (MBC) patients than covered by current approvals, which require a germline BRCA1/2 seque
Autor:
Brian M. Alexander, Miriam J. Haviland, Nadine Tung, Judy Garber, Edward T. Richardson, Laura C. Collins, Vanda F. Torous, Jaymin M. Patel, Gordon J. Freeman, Michele R. Hacker, Stuart J. Schnitt, Andrew J. Goss, Tessa Nalven, Larissa J. Lee
Publikováno v:
npj Breast Cancer, Vol 6, Iss 1, Pp 1-6 (2020)
NPJ Breast Cancer
NPJ Breast Cancer
Retinoblastoma protein (Rb) is a product of the RB tumor suppressor gene. Its expression is highly prevalent in luminal breast cancers and is critical to the success of cyclin-dependent kinase (CDK) 4/6 inhibitor therapy. Expression of Rb in triple-n
Autor:
Andrew R. Green, David L Goode, Simone M Rowley, Jia-Min Pang, Kylie L. Gorringe, Ian G. Campbell, Tanjina Kader, Dane Cheasley, Emad A. Rakha, Prue Hill, G. Bruce Mann, Kenneth Elder, Niko Thio, Stephen B. Fox, David J Byrne, Timothy Semple, Islam M. Miligy, Magnus Zethoven
Publikováno v:
npj Breast Cancer, Vol 6, Iss 1, Pp 1-13 (2020)
NPJ Breast Cancer
NPJ Breast Cancer
Intraductal papillomas (IDP) are challenging breast findings because of their variable risk of progression to malignancy. The molecular events driving IDP development and genomic features of malignant progression are poorly understood. In this study,
Autor:
Michael Vallis, Som D. Mukherjee, Kathleen I. Pritchard, Roanne J. Segal, B. Findlay, André Robidoux, Pamela J. Goodwin, Gregory R. Pond, Mark Levine, Julie R. Gralow, Jennifer A. Ligibel
Publikováno v:
npj Breast Cancer, Vol 6, Iss 1, Pp 1-7 (2020)
NPJ Breast Cancer
NPJ Breast Cancer
Obesity has been associated with poor breast cancer (BC) outcomes. We investigated whether a standardized, telephone-based weight loss lifestyle intervention in the adjuvant setting would impact BC outcomes. We conducted a multicenter trial randomizi
Autor:
Jeanette Dupont Jensen, Torsten O. Nielsen, Eva Balslev, Ann Knoop, Wesley Buckingham, Anne-Vibeke Lænkholm, Maj-Britt Jensen, Sean Ferree, Vesna Glavicic, Henning T. Mouridsen, Bent Ejlertsen, Dorte Nielsen
Publikováno v:
npj Breast Cancer, Vol 6, Iss 1, Pp 1-9 (2020)
Jensen, M B, Lænkholm, A V, Balslev, E, Buckingham, W, Ferree, S, Glavicic, V, Dupont Jensen, J, Søegaard Knoop, A, Mouridsen, H T, Nielsen, D, Nielsen, T O & Ejlertsen, B 2020, ' The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients ', npj Breast Cancer, vol. 6, 7 . https://doi.org/10.1038/s41523-020-0148-0
Jensen, M-B, Lænkholm, A-V, Balslev, E, Buckingham, W, Ferree, S, Glavicic, V, Dupont Jensen, J, Søegaard Knoop, A, Mouridsen, H T, Nielsen, D, Nielsen, T O & Ejlertsen, B 2020, ' The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients ', npj Breast Cancer, vol. 6, 7 . https://doi.org/10.1038/s41523-020-0148-0
NPJ Breast Cancer
Jensen, M B, Lænkholm, A V, Balslev, E, Buckingham, W, Ferree, S, Glavicic, V, Dupont Jensen, J, Søegaard Knoop, A, Mouridsen, H T, Nielsen, D, Nielsen, T O & Ejlertsen, B 2020, ' The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients ', npj Breast Cancer, vol. 6, 7 . https://doi.org/10.1038/s41523-020-0148-0
Jensen, M-B, Lænkholm, A-V, Balslev, E, Buckingham, W, Ferree, S, Glavicic, V, Dupont Jensen, J, Søegaard Knoop, A, Mouridsen, H T, Nielsen, D, Nielsen, T O & Ejlertsen, B 2020, ' The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients ', npj Breast Cancer, vol. 6, 7 . https://doi.org/10.1038/s41523-020-0148-0
NPJ Breast Cancer
The DBCG89D trial randomized high-risk early breast cancer patients to adjuvant CMF (cyclophosphamide, methotrexate and fluorouracil) or CEF (cyclophosphamide, epirubicin and fluorouracil). Prosigna assays were performed by researchers with no access
Autor:
Kala Visvanathan, Edward Gabrielson, Joseph Geradts, Antonio C. Wolff, Danielle Meir-Levi, Meredith M. Regan, Mary Jo Fackler, Jeffrey R. Marks, Leslie Cope, Charles F. Lynch, Giuseppe Viale, Christopher B. Umbricht, Soonweng Cho, Saraswati Sukumar, Kathleen Wilsbach
Publikováno v:
npj Breast Cancer, Vol 6, Iss 1, Pp 1-6 (2020)
NPJ Breast Cancer
NPJ Breast Cancer
We lack tools to risk-stratify triple-negative breast cancer (TNBC). Our goal was to develop molecular tools to predict disease recurrence. Methylation array analysis was performed on 110 samples treated by locoregional therapy obtained from institut